NetworkNewsWire Announces Publication Highlighting Big Pharma''s Appetite for M&A Possibilities in Cannabis
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 11/08/17 -- ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
The publication, titled, "Biotech M&A Momentum Attractive for Cannabinoid R&D Space," highlights biotech companies creating cannabis-based products to treat a range of medical disorders in the massive market space.
To view the full publication, visit:
"Morgan Stanley''s research team in January 2017 forecast that biotech-pharmaceutical companies - with a combined $75 billion in cash on hand - would strategize to boost revenue growth through mergers and acquisitions of smaller companies with high-potential product pipelines (). Growth via strategic acquisition makes more sense to cost-conscious Big Pharma than does shelling out $2.55 billion () to develop a new drug in-house. With growing interest in the convergence of cannabis and medicine, companies like , which has an innovative biosynthesis technology that addresses the regulatory concerns associated with consistent pharmaceutical-grade cannabinoids and logistical constraints on development, may find themselves on the radar of Big Pharma.
"With a market cap of just over US$45 million, InMed boasts a rare position as the owner of proprietary biosynthesis and bioinformatics technologies () and is developing the technology to produce commercial quantities of cannabinoids without the production and maintenance costs and pitfalls associated with chemically-derived cannabinoid synthetics. InMed''s approach to developing biosynthetic cannabinoids combines the inherent safety and established efficacy of natural drug structures with the kind of quality-controlled pharmaceutical manufacturing required by the FDA. This process also grants the company direct access to overlooked minor cannabinoids that are currently economically unfeasible to extract from the plant. Combining these advantages with the company''s ability to rapidly identify and develop additional indications such as the company''s INM-085 for the >$5 billion glaucoma market, or INM-405 for pain, results in all the right ingredients to potentially make InMed one of the sector''s next big stars or M&A targets."
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed''s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.
For more information, visit .
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today''s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company''s SEC filings. These risks and uncertainties could cause the company''s actual results to differ materially from those indicated in the forward-looking statements.
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.11.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 1527797
Anzahl Zeichen: 9008
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 349 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NetworkNewsWire Announces Publication Highlighting Big Pharma''s Appetite for M&A Possibilities in Cannabis
"
steht unter der journalistisch-redaktionellen Verantwortung von
NetworkNewsWire (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
